MENT and MK-2866 Interaction

Monitor
Mechanism-based 46% confidence

MENT and MK-2866 have an interaction requiring monitoring for interaction with 46% confidence. Both MENT and MK-2866 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Both compounds affect the gonads and heart and liver, so monitoring these systems is recommended.

Compound Profiles

MENT

19-Nor Anabolic Steroid | Experimental TRT Alternative

MENT binds to the androgen receptor with high affinity, estimated at roughly 10 times the potency of testosterone, driving robust activation of AR-dependent gene transcription pathways responsible for protein synthesis, nitrogen retention, and satellite cell proliferation in skeletal muscle. Its 7-alpha methyl group renders it resistant to 5-alpha reductase, meaning it is not converted to a reduced metabolite in androgen-sensitive tissues the way testosterone is converted to DHT or nandrolone is converted to DHN.

Half-life: ~40 minutes (acetate ester) Typical dose: 5-25 mg/day (acetate) anabolic, sexual health
5 alpha reductaseandrogen receptorepo receptorestrogen receptor androgenicaromatase inhibitorblood pressure raisingcarcinogenic risk
View full profile

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Combined Organ Load

Gonads
elevated
Heart
moderate
Liver
moderate

Shared Safety Flags

2x 2 androgenic compounds (MENT, MK-2866). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds share the carcinogenic-risk safety flag (MENT, MK-2866). Monitor accordingly.
2x 2 HPTA-suppressive compounds (MENT, MK-2866). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (MENT, MK-2866). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take MENT with MK-2866?

Yes, but with caution. Both MENT and MK-2866 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Regular monitoring is advised.

Is MENT and MK-2866 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, carcinogenic risk, hpta suppressive, lipid disrupting. Monitor accordingly.

What are the interactions between MENT and MK-2866?

Both MENT and MK-2866 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. This assessment has 46% confidence and is inferred from pharmacological mechanism analysis.

How should I time MENT and MK-2866?

MENT has a half-life of ~40 minutes (acetate ester) and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: MENT vs MK-2866

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.